tesamorelin growth hormone: Frequently asked questions

Mild erythema and induration at the injection site occur in 20–30% of users during the first 2–3 weeks as the immune system encounters the synthetic GHRH analog. Persistent reactions beyond week 4 suggest either improper injection technique (injecting into dermis rather than subcutaneous tissue) or contamination during reconstitution. Rotate injection sites across the abdomen to prevent localized inflammation, and ensure bacteriostatic water—not sterile water—is used for reconstitution, as the benzyl alcohol preservative reduces bacterial growth risk.

Tesamorelin in solution degrades rapidly above 8°C—a single 12-hour temperature excursion at 20–25°C can reduce potency by 30–50%, and the degradation is irreversible. The peptide's tertiary structure denatures when thermal energy exceeds hydrogen bond stability, and neither visual inspection nor pH testing can detect this loss. If room-temperature exposure occurred, discard the vial and reconstitute a fresh dose—continuing with degraded peptide wastes weeks of protocol time without producing valid data.

Verify dosing compliance first—missed doses during the first 8 weeks delay enzymatic upregulation and push the timeline backward. If dosing has been consistent, measure IGF-1 levels: if IGF-1 hasn't increased ≥30% from baseline, the issue is likely blunted pituitary response (common in populations >60 years) or degraded peptide from improper storage. Non-responders with normal IGF-1 elevation but minimal VAT loss may have insulin resistance severe enough to override lipolytic signaling—adding metformin or other insulin sensitizers to the protocol sometimes restores responsiveness.

Reconstituted tesamorelin degrades rapidly at room temperature. Expect 20–30% potency loss after 48 hours at 25°C. If refrigeration isn't available during travel, carry lyophilised vials and reconstitute daily using pre-filled bacteriostatic water syringes. Medical-grade cooling pouches like the FRIO wallet maintain 2–8°C for 36–48 hours using evaporative cooling. No ice or electricity required. Alternatively, dose before departure and resume immediately upon return; missing 2–3 doses won't reset visceral fat reduction progress.

Elevated fasting glucose during the first 4–6 weeks is common and typically transient. GH transiently impairs insulin sensitivity as part of its counter-regulatory hormone function. Monitor HbA1c at 8 and 16 weeks; sustained elevation above 6.0% warrants dose reduction or discontinuation. Unlike synthetic GH, tesamorelin rarely causes persistent hyperglycemia because the pulsatile secretion pattern allows insulin sensitivity to normalize between GH peaks. If glucose remains elevated beyond 8 weeks, consider metformin co-administration. 500mg twice daily restores insulin sensitivity without interfering with GH release.

Verify dose accuracy first. If you're reconstituting with more than 2.1mL diluent, you're underdosing every injection. Request IGF-1 testing to confirm the peptide is triggering hepatic IGF-1 synthesis; baseline IGF-1 below 100 ng/mL predicts poor response. If IGF-1 rises appropriately but fat reduction stalls, the issue is likely dietary. Tesamorelin mobilizes visceral fat into circulation, but without a caloric deficit, that fat gets re-esterified and stored. The peptide creates the metabolic opportunity; energy balance determines the outcome.

Discard the vial and reconstitute a fresh dose. Tesamorelin is a 44-amino-acid peptide with a specific tertiary structure required for GHRH receptor binding. Exposure to temperatures above 8°C for more than 2–3 hours causes irreversible denaturation of that structure, breaking disulfide bonds and disrupting the lipophilic modification that extends its half-life. The denatured peptide may appear visually identical (clear, colorless solution) but will have no biological activity. There is no way to test potency at home, and injecting denatured peptide wastes the dose while exposing the subject to potential immunogenic fragments.

Verify reconstitution technique first. The most common error is injecting bacteriostatic water too forcefully, causing foam formation that denatures the peptide. Draw the water slowly, inject it down the side of the vial rather than directly onto the lyophilized powder, and allow it to dissolve passively without shaking. If technique is correct, the next possibility is injection timing: administering tesamorelin in the morning may conflict with the body's natural GH trough, producing smaller pulses. Shift to evening dosing 30–60 minutes before sleep to align with the circadian GH surge. If neither adjustment produces results, consider baseline GH receptor sensitivity. Individuals with metabolic syndrome or chronic hyperinsulinemia may exhibit blunted GH responsiveness that requires higher doses or combination therapy with metformin to restore insulin sensitivity.

Yes, and typically within 7–14 days. Tesamorelin does not suppress endogenous GH production. It stimulates it. So there is no rebound hyposomatotropism upon cessation, unlike exogenous GH which causes secondary hypogonadism lasting weeks to months. Serum IGF-1 levels return to pre-treatment baseline within 10–14 days as the peptide clears and pituitary GH secretion normalizes. However, the metabolic and body composition changes achieved during treatment. Reduced visceral fat, improved lipid profiles. Are not permanent. Clinical data from extension studies show that visceral adipose tissue begins to re-accumulate within 3–6 months of stopping tesamorelin unless caloric intake and activity levels are adjusted to maintain the new metabolic state.

No functional benefit and potential harm. Exogenous GH suppresses endogenous GH production through negative feedback at the hypothalamus and pituitary. Administering tesamorelin in this context is pharmacologically futile because the GHRH receptors tesamorelin targets are downregulated, and the pituitary somatotrophs are already in a state of suppressed activity. Adding tesamorelin will not produce additional GH release. Furthermore, combining the two increases IGF-1 to supraphysiologic levels without improving the risk-benefit ratio, elevating the probability of adverse events including insulin resistance, carpal tunnel syndrome, and arthralgias. The rational approach is to choose one or the other. Tesamorelin for axis preservation, exogenous GH for maximum IGF-1 elevation. Not both.

Reduce the dose to 1mg nightly for one week, then reassess. Joint pain and carpal tunnel are dose-dependent side effects caused by elevated IGF-1 stimulating synovial fluid production and soft tissue swelling. The symptoms resolve within 5–7 days of dose reduction in 85% of cases. If pain persists at 1mg, discontinue for 48 hours to allow IGF-1 levels to normalise, then restart at 0.5mg and titrate upward by 0.25mg weekly. Some individuals have genetic variations in IGF-1 receptor density that make them hyper-responsive to even physiological GH elevations.

Discard the vial and reconstitute a fresh dose. Tesamorelin undergoes irreversible aggregation above 8°C. The peptide chains clump into insoluble fibrils that cannot bind GHRH receptors. Even if the solution appears clear, bioactivity drops to near-zero within 2–4 hours at room temperature. You cannot reverse this process by re-refrigerating. Injecting degraded peptide won't harm you, but it delivers no GH-stimulating effect. You're wasting the dose.

Resume at your previous dose without restarting from zero. Missing three doses won't erase prior progress, but it may temporarily reduce receptor sensitivity. Monitor your response over the next week. If you notice reduced appetite suppression or return of abdominal bloating (indirect markers of GH activity), drop to 1mg for three days before returning to 2mg. The receptor desensitisation caused by erratic dosing is reversible but requires re-establishing consistent signalling.